We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 27, 2020

Phase Ib Clinical Trial of Vantictumab + Paclitaxel in Patients With Locally Advanced or Metastatic HER2− Breast Cancer

Breast Cancer Research and Treatment

 

Additional Info

Breast Cancer Research and Treatment
Phase Ib Clinical Trial of the Anti-Frizzled Antibody Vantictumab (OMP-18R5) Plus Paclitaxel in Patients With Locally Advanced or Metastatic HER2-Negative Breast Cancer
Breast Cancer Res Treat 2020 Nov 01;184(1)53-62, JR Diamond, C Becerra, D Richards, A Mita, C Osborne, J O'Shaughnessy, C Zhang, R Henner, AM Kapoun, L Xu, B Stagg, S Uttamsingh, RK Brachmann, A Farooki, M Mita

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading